DUBLIN--(BUSINESS WIRE)--Dec 21, 2022--

The “Epigenetics Drugs & Diagnostic Technologies Market, by Type and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

Market Dynamics

Increasing prevalence of cancer is expected to drive the market growth during the forecast period.

According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).

Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.

The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market

Detailed Segmentation:

Global Epigenetics Drugs & Diagnostic Technologies Market, By Type:

• Epigenetic Drugs
• DNMT Inhibitors
• Azacitidine
• Decitabine
• HDAC Inhibitors
• Vorinostat
• Romidepsin
• Others
• Epigenetics Diagnostic Technologies
• DNAMethylation
• CHIP Technology

Global Epigenetics Drugs & Diagnostic Technologies Market, By Region:

• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa

Company Profiles

• Regenacy Pharmaceuticals, Inc.
• Astex Pharmaceuticals
• 4SC AG
• CellCentric Ltd.
• Celleron Therapeutics Ltd.
• Bristol-Myers Squibb Company
• Oryzon Genomics S.A.
• ChromaMedicine, Inc.
• Epizyme, Inc.
• EpiGentek Group Inc.

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Epigenetic Drugs & Diagnostic Technologies Market - Impact of Coronavirus (Covid-19) Pandemic

5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2017 - 2030, (US$ Mn)

6. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2017 - 2030, (US$ Mn)

7. Competitive Landscape

8. Section

For more information about this report visit https://www.researchandmarkets.com/r/abngu5

View source version on businesswire.com:https://www.businesswire.com/news/home/20221221005273/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: GENETICS PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 12/21/2022 06:44 AM/DISC: 12/21/2022 06:45 AM

http://www.businesswire.com/news/home/20221221005273/en